FOR IMMEDIATE RELEASE
November 22, 2021

The Global Colon Cancer Association Urges Congress To Abandon Harmful Drug Price-Setting Policies Within The Build Back Better Act

WASHINGTON, D.C. – Today, the Global Colon Cancer Association (GCCA) sent a letter signed by 27 other patient groups calling on Members of the 117th Congress to address several drug pricing provisions within the Build Back Better Act that threatens to crush the pipeline for new drugs, biologics, and biosimilars.

In particular, this bill would subject medicines to potential government price-setting well before their exclusivities expire. Additionally, permitting the government to set prices of some medicines creates a disincentive for generic and biosimilar medicines to be developed.

"This proposal undermines the very steps Congress has taken to promote critical research into treatments for the most serious illnesses," said Andrew Spiegel, Executive Director of the GCCA. "By picking the winners and losers of biopharmaceutical innovation, these policies unwind much of the progress that has been made in incentivizing the development of innovative medicines to treat cancer and rare disease."

While the GCCA appreciates the inclusion of several policies that would lower out-of-pocket costs for patients, any policy that negatively impacts research into rare, pediatric, and orphan diseases should be further evaluated to ensure it would not ruin seriously-ill patients chances of accessing future cures and treatments.

The full text of the letter to Congress and the full list of signers can be viewed at www.globalcca.org/advocacy.

###

ABOUT GCCA
The Global Colon Cancer Association is the voice for the millions of colon cancer (CRC) patients worldwide, advocating for patient-centered policy around the globe to ensure increased awareness and screening, access to quality medical treatments and help our member organizations collaborate, innovate and leverage the full potential of effectuating change.